Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Editas Medicine

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Editas Medicine reports positive clinical data and strategic advancements

Editas Medicine's Q4 2022 earnings call highlighted positive clinical data, strong financial positioning, and strategic advancements in genome editing medicines.
While facing challenges in hiring key personnel, regulatory negotiations, and strategic realignment, the company is well-positioned for therapeutic advancements and market growth.
Opportunities lie in replicating clinical success, strategic partnerships, and advancements in pipeline development, supported by strong collaborations and financial prospects.
Overall, Editas Medicine's performance, strengths, challenges, and opportunities reflect a company poised for continued growth and innovation in the genome editing space.

Editas Medicine excels in Q1 with promising trials and regulatory progress

Editas Medicine's Q1 performance was strong, supported by promising clinical trial data and regulatory advancements.
The company's focus on gene editing for hemoglobinopathies and strong IP position are key strengths.
Challenges include differentiation from competitors and legal uncertainties, while opportunities lie in expansion and regulatory progress.
Overall, Editas Medicine is well-positioned for growth in the gene editing market.

Editas Medicine reports positive data, raises funds, and faces challenges

Editas Medicine shows strong performance with positive clinical data and financial raise
Facing challenges in pipeline adjustment and FDA discussions for facility planning
Opportunities lie in expanding trials, partnerships, and enhancing R&D focus

Editas Medicine advances EDIT-301 program, poised for gene therapy leadership

Editas Medicine is making significant progress with EDIT-301, showcasing confidence in their gene editing capabilities and operational readiness.
While facing challenges in safety monitoring and differentiation, the company's strategic hires, strong IP portfolio, and focus on regulatory pathways provide a solid foundation for growth.
With a clear roadmap for clinical data presentation, manufacturing scaling, and regulatory submissions, Editas is well-positioned to capitalize on opportunities in gene editing therapies.

Editas Medicine exceeds enrollment goals and showcases promising clinical data

Editas Medicine's Q4 2023 Earnings Call showcased strong performance in enrollment, clinical data, and financials. The company's strengths lie in its research capabilities, cash position, and progress in key trials. Challenges include addressing analyst queries and optimizing manufacturing processes.

Editas Medicine reports robust Q1 performance and advances in gene editing

Editas Medicine's Q1 2024 performance reflects solid revenue and strong financial reserves, driven by R&D investments in the Renace program.
The company's strengths lie in its financial stability, advancing in vivo capabilities, and fostering strong collaborations for future growth.
Challenges include legal uncertainties, operational optimizations, and strategic complexities in therapeutic development.
Opportunities abound in driving Renace, regulatory progress for Reni-cel, and leveraging innovative in vivo approaches for unique indications.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Studies in non-human primates demonstrated nearly 100% gene editing knockout of endogenous RHO gene and more than 30% replacement protein levels

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology Conference

Editas Medicine, Inc. (NASDAQ:EDIT ) Q1 2022 Results Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Jim Mullen - Chief Executive Officer Mark Shearman - Chief Scientific Officer Michelle Robertson - Chief Financial Officer Charlene Stern - General Counsel. Conference Call Participants Joon Lee - Truist Joel Beatty - Baird Dae Gon Ha - Stifel Steven Seedhouse - Raymond James Rick Bienkowski - SVB Securities Luca Issi - RBC Capital Liisa Bayko - Evercore ISI Operator Good morning and welcome to the Editas Medicine First Quarter 2022 Conference Call.

Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q1 2022 Results - Earnings Call Transcript

Appointed Gilmore O'Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman

Editas Medicine Announces First Quarter 2022 Results and Business Updates

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that four abstracts have been accepted for presentation, including three oral presentations, at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held in Washington, D.C., and virtually, May 16 – 19, 2022. The Company is presenting data on its pipeline and platform technologies to support ongoing development programs.

Editas Medicine to Present Pipeline and Platform Data Demonstrating Progress Towards Developing Transformative Gene Editing Medicines at the American Society of Gene and Cell Therapy Annual Meeting

Editas (EDIT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday, May 4, 2022, at 8:00 a.m. ET to provide a corporate update and results for the first quarter of 2022.

Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia. The FDA previously granted Rare Pediatric Disease designation to EDIT-301 for the treatment of sickle cell disease.

Editas Medicine Receives FDA Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Beta Thalassemia

CRISPR Therapeutics

Intellia Therapeutics

They point to trouble for investors counting on a rebound.

3 Ominous Reasons to Avoid This Biotech Pioneer

James C. Mullen to Serve as Executive Chairman

Editas Medicine Appoints Gilmore O'Neill as Chief Executive Officer

Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study

Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient

Editas Medicine Announces Dosing of First Pediatric Patient in the BRILLIANCE Clinical Trial of EDIT-101 for LCA10

Preclinical data demonstrate that edited iNK cells result in increased persistence, enhanced anti-tumor activity and extended survival supporting continued development as a novel therapeutic approach for solid tumors

Editas Medicine Reports Engineered iNK Cell Preclinical Data at American Association for Cancer Research Annual Meeting

Editas (EDIT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Editas (EDIT) Soars 6.3%: Is Further Upside Left in the Stock?

Editas has two CRISPR genome editing techniques which are CRISPR/Cas9 and CRISPR/Cas12a.

Editas: CRISPR Gene Editing Biotech With Promising Future

Editas Medicine, Inc. (EDIT) Presents at Cowen 42nd Annual Healthcare Conference (Transcript)

The U.S. Patent and Trademark Office has ruled in favor of the Broad Institute of MIT and Harvard in a dispute over the patents around CRISPR gene-editing technology. The decision is part of a long-running legal battle brought by two universities and one of the founders of the gene-editing.

Editas Medicine Stock Jumps As Patent Office Rules In Favor Of Broad's CRISPR Patents

CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, announced today the U.S. Patent and Trademark Office (USPTO) issued another favorable decision to the Broad Institute, Inc. (Broad) involving specific patents for CRISPR/Cas9 editing in human cells. Pending an appeal to the Federal Circuit, this decision ends the U.S. patent interference between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and Broad.

Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent Interference

Editas Medicine, Inc. (EDIT) CEO Jim Mullen on Q4 2021 Results - Earnings Call Transcript

EDIT-101 Phase 1/2 BRILLIANCE trial enrolling mid-dose pediatric cohort; clinical data update expected in 2H 2022

Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates

Aerie Pharmaceuticals

Emergent BioSolutions

Moderna

Vir Biotechnology

Let us take a look at five biotech/drug companies, namely, MRNA, EDIT, VIR, EBS and AERI, which are due to release their quarterly results on Feb 24.

Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & More

Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should Know

CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, February 24, 2022, at 8:00 a.m. ET to provide a corporate update and results for the fourth quarter and full year 2021.

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update

Sangamo Therapeutics

Our theme of Gene Editing stocks continues to underperform, declining by about 16% year-to-date in 2022, compared to the S&P 500 which is down by about 6% over the same period. The theme also declined by about 11% in 2021.

The Sell Off In Gene Editing Stocks Continues. Time To Buy?

Editas Medicine Inc EDIT has fired Chief Medical Officer Lisa Michaels just 15 months into her tenure at the Company. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Editas Suddenly Terminates Chief Medical Officer Without An Explanation

Krystal Biotech

For these two companies, the rewards could end up outweighing the risks.

News for Editas Medicine Stock (EDIT)